Immunovaccine

The Company’s DepoVax™ platform is a patented formulation that provides controlled and prolonged exposure of antigens plus adjuvant to the immune system. Immunovaccine has advanced two DepoVax™-based cancer vaccines into Phase 1 human clinical trials. The Company is also advancing a broad infectious diseases pipeline including vaccines in such indications as malaria, respiratory syncytial virus (RSV) and anthrax. In addition to the Company’s human health vaccine strategy, it continues to capture value from animal health vaccine applications. Immunovaccine has key partnerships in the animal health sector including an agreement with Zoetis, former animal health division of Pfizer.
Type
Public
HQ
Halifax, CA
Founded
2000
Employees
23 (est)

Key People at Immunovaccine

Kimberly Stephens

Kimberly Stephens

CFO
Marc Mansour

Marc Mansour

COO

Immunovaccine Locations

Halifax, CA

Immunovaccine Metrics

Immunovaccine Summary

Founding Date

2000

Market capitalization

$83.4 M

Closing share price

$0.78

Immunovaccine Market Value History

Immunovaccine Online Presence

Immunovaccine News

Immunovaccine Company Life

You may also be interested in